Dharminder Chauhan

Dharminder Chauhan's AcademicInfluence.com Rankings

Dharminder Chauhan

Biology

#9586

World Rank

#12809

Historical Rank

Cell Biology

#415

World Rank

#425

Historical Rank

Molecular Biology

#1331

World Rank

#1358

Historical Rank

Biochemistry

#1477

World Rank

#1603

Historical Rank

biology Degrees

Download Badge

Biology

Dharminder Chauhan's Degrees

PhD Biochemistry University of California, Berkeley
Masters Molecular Biology Stanford University

Why Is Dharminder Chauhan Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Dharminder Chauhan's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. (2001) (1584)
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. (2001) (909)
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. (2000) (902)
NF-κB as a Therapeutic Target in Multiple Myeloma* (2002) (854)
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. (2002) (801)
Molecular sequelae of proteasome inhibition in human multiple myeloma cells (2002) (769)
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. (2003) (730)
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. (2002) (670)
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. (2005) (661)
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. (2004) (652)
Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. (1996) (603)
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. (2005) (593)
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. (2003) (589)
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. (2004) (570)
Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma (2001) (505)
Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications (2002) (491)
A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. (2012) (466)
NF-kappa B as a therapeutic target in multiple myeloma. (2002) (464)
Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. (1993) (459)
Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. (2001) (440)
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. (2005) (431)
The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma: therapeutic applications (2001) (404)
Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. (2002) (395)
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. (2007) (395)
Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. (2006) (349)
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. (2009) (347)
Bone marrow microenvironment and the identification of new targets for myeloma therapy (2009) (332)
Antimyeloma activity of heat shock protein-90 inhibition. (2005) (327)
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application (2005) (317)
Molecular sequelae of histone deacetylase inhibition in human malignant B cells. (2003) (309)
Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. (1997) (302)
In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells (2011) (289)
Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. (2004) (279)
A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. (2014) (266)
Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells. (1996) (252)
Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. (2003) (244)
Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. (2005) (242)
Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. (2009) (239)
Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. (2003) (238)
Dysfunctional T regulatory cells in multiple myeloma. (2006) (236)
NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. (2003) (226)
Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. (2006) (224)
A novel Bcl-2/Bcl-XL/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma (2007) (219)
JNK-dependent Release of Mitochondrial Protein, Smac, during Apoptosis in Multiple Myeloma (MM) Cells* (2003) (215)
Apaf-1/Cytochrome c-independent and Smac-dependent Induction of Apoptosis in Multiple Myeloma (MM) Cells* (2001) (213)
Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease (2010) (210)
Novel therapies targeting the myeloma cell and its bone marrow microenvironment. (2001) (209)
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. (2011) (204)
Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling. (2003) (203)
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma (2008) (202)
Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. (2007) (201)
Cytochrome c-dependent and -independent Induction of Apoptosis in Multiple Myeloma Cells* (1997) (198)
CD40 ligand triggered interleukin-6 secretion in multiple myeloma. (1995) (197)
A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. (2010) (196)
The proteasome and proteasome inhibitors in multiple myeloma (2017) (192)
SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. (2000) (191)
Cytokines modulate telomerase activity in a human multiple myeloma cell line. (2002) (189)
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma (2006) (189)
Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. (2008) (187)
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. (2004) (185)
Nuclear Factor-κB p65 Mediates Tumor Necrosis Factor α-induced Nuclear Translocation of Telomerase Reverse Transcriptase Protein (2003) (180)
Targeting PD1–PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells (2015) (178)
Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. (2005) (177)
Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma (2003) (177)
Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism (1997) (175)
Identification of genes regulated by Dexamethasone in multiple myeloma cells using oligonucleotide arrays (2002) (170)
The development of a model for the homing of multiple myeloma cells to human bone marrow. (1997) (170)
Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. (2005) (169)
Vascular Endothelial Growth Factor-induced Migration of Multiple Myeloma Cells Is Associated with β1 Integrin- and Phosphatidylinositol 3-Kinase-dependent PKCα Activation* (2001) (168)
Proteasome inhibitor therapy in multiple myeloma (2005) (163)
VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis. (2004) (162)
5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells (2007) (162)
Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis. (2004) (161)
Characterization of adhesion molecules on human myeloma cell lines. (1992) (160)
Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. (2002) (158)
Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. (2003) (157)
A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. (2005) (156)
Essential Role of Caveolae in Interleukin-6- and Insulin-like Growth Factor I-triggered Akt-1-mediated Survival of Multiple Myeloma Cells* (2003) (154)
Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). (2004) (153)
Identification of genes modulated in multiple myeloma using genetically identical twin samples. (2004) (151)
JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells. (2007) (143)
Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132. (2006) (142)
Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells. (2003) (140)
A novel proteasome inhibitor NPI-0052 as an anticancer therapy (2006) (140)
Proteasome inhibition in multiple myeloma: therapeutic implication. (2005) (134)
The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. (2004) (131)
Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. (2004) (130)
Neutralizing B-Cell–Activating Factor Antibody Improves Survival and Inhibits Osteoclastogenesis in a Severe Combined Immunodeficient Human Multiple Myeloma Model (2007) (129)
A pivotal role for Mcl-1 in Bortezomib-induced apoptosis (2008) (128)
The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. (2007) (127)
The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. (2002) (127)
Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes. (2003) (126)
2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells. (2002) (125)
Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti‐myeloma activity in vitro and in vivo (2010) (125)
Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. (2012) (122)
Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. (2003) (119)
Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein. (2003) (118)
Structure-Guided Development of a Potent and Selective Non-covalent Active-Site Inhibitor of USP7. (2017) (118)
RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells (1999) (117)
Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). (2006) (116)
MLN120B, a Novel IκB Kinase β Inhibitor, Blocks Multiple Myeloma Cell Growth In vitro and In vivo (2006) (114)
Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells (2007) (112)
PR‐924, a selective inhibitor of the immunoproteasome subunit LMP‐7, blocks multiple myeloma cell growth both in vitro and in vivo (2011) (111)
Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. (2007) (110)
Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. (2003) (110)
FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. (2005) (108)
p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells (2004) (107)
Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. (2010) (107)
Transforming Growth Factor β Receptor I Kinase Inhibitor Down-Regulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment (2004) (105)
Gene expression analysis of B‐lymphoma cells resistant and sensitive to bortezomib * (2006) (104)
Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation. (2002) (103)
Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. (1999) (100)
Interleukin-6 promotes multiple myeloma cell growth via phosphorylation of retinoblastoma protein. (1996) (98)
Combination Therapy with Interleukin-6 Receptor Superantagonist Sant7 and Dexamethasone Induces Antitumor Effects in a Novel SCID-hu In vivo Model of Human Multiple Myeloma (2005) (96)
Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma. (2009) (93)
MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells. (1997) (90)
Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. (2008) (90)
Interleukin-6 Overcomes p21WAF1 Upregulation and G1 Growth Arrest Induced by Dexamethasone and Interferon-γ in Multiple Myeloma Cells (1997) (90)
Caveolin-1 Is Required for Vascular Endothelial Growth Factor-Triggered Multiple Myeloma Cell Migration and Is Targeted by Bortezomib (2004) (89)
The malignant clone and the bone-marrow environment. (2007) (89)
Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. (2016) (88)
Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma. (2003) (87)
GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment. (2004) (87)
HDAC Inhibition by LBH589 Affects Phenotype and Function of Human Myeloid Dendritic Cells (2010) (87)
Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity. (2013) (83)
Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays. (2003) (81)
Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. (2004) (81)
Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma (2004) (81)
Cell surface expression and functional significance of adhesion molecules on human myeloma‐derived cell lines (1994) (80)
Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications. (2009) (80)
Identification and validation of novel therapeutic targets for multiple myeloma. (2005) (80)
Inhibition of USP10 induces degradation of oncogenic FLT3. (2017) (80)
Biologic sequelae of c-Jun NH2-terminal kinase (JNK) activation in multiple myeloma cell lines (2003) (78)
Mechanisms of cell death and survival in multiple myeloma (MM): Therapeutic implications (2003) (78)
Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. (2008) (77)
New Proteasome Inhibitors in Myeloma (2012) (76)
Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib (2009) (76)
Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma. (2000) (74)
Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma. (2003) (73)
CD40 ligand triggers interleukin-6 mediated B cell differentiation. (1996) (72)
Emerging Therapies for Multiple Myeloma (2006) (71)
CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines. (2000) (71)
Adenovirus vector-based purging of multiple myeloma cells. (1998) (70)
In Vitro and In Vivo Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells (2013) (70)
Critical Role for Hematopoietic Cell Kinase (Hck)-mediated Phosphorylation of Gab1 and Gab2 Docking Proteins in Interleukin 6-induced Proliferation and Survival of Multiple Myeloma Cells* (2004) (68)
Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance (2017) (68)
Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells (2011) (68)
Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling. (2008) (68)
Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells. (2012) (67)
Regulatory B cell-myeloma cell interaction confers immunosuppression and promotes their survival in the bone marrow milieu (2017) (67)
Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1. (2016) (67)
Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus gene sequences. (1999) (66)
Preclinical Activity of the Oral Proteasome Inhibitor MLN9708 in Myeloma Bone Disease (2014) (66)
MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. (2006) (65)
Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. (2009) (64)
The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications (2011) (64)
Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma (2009) (64)
Detection of Kaposi's sarcoma herpesvirus DNA sequences in multiple myeloma bone marrow stromal cells. (1999) (64)
Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway (2005) (63)
A Novel Hypoxia-Selective Epigenetic Agent RRx-001 Triggers Apoptosis and Overcomes Drug Resistance in Multiple Myeloma Cells (2016) (63)
Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo (2009) (62)
A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells. (2011) (62)
Targeting proteasome ubiquitin receptor Rpn13 in multiple myeloma (2016) (61)
Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI‐0052 (marizomib) in a human plasmacytoma xenograft murine model (2010) (61)
Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells (2003) (61)
Interleukin-11 promotes accessory cell-dependent B-cell differentiation in humans. (1992) (60)
Role of interleukin 6 in the growth of myelomaderived cell lines (1992) (59)
SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. (2005) (58)
Intracellular Protein Degradation and Its Therapeutic Implications (2005) (58)
Anti-estrogens induce apoptosis of multiple myeloma cells. (1998) (57)
p38 mitogen‐activated protein kinase inhibitor LY2228820 enhances bortezomib‐induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications (2008) (57)
Ku86 Variant Expression and Function in Multiple Myeloma Cells Is Associated with Increased Sensitivity to DNA Damage1 (2000) (57)
Oncostatin M induces association of Grb2 with Janus kinase JAK2 in multiple myeloma cells (1995) (57)
Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells (2017) (57)
Antimyeloma Activity of a Multitargeted Kinase Inhibitor, AT9283, via Potent Aurora Kinase and STAT3 Inhibition Either Alone or in Combination with Lenalidomide (2011) (57)
Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341 (2004) (56)
Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma. (2007) (55)
The therapeutic role of targeting protein kinase C in solid and hematologic malignancies (2007) (55)
Muc-1 Core Protein Is Expressed on Multiple Myeloma Cells and Is Induced by Dexamethasone (1999) (54)
Recombinant humanized anti‐CD40 monoclonal antibody triggers autologous antibody‐dependent cell‐mediated cytotoxicity against multiple myeloma cells (2003) (53)
Cytokines and signal transduction. (2005) (51)
Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study. (2020) (51)
Targeting proteasomes as therapy in multiple myeloma. (2008) (51)
Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma (2018) (50)
A phase 1 clinical trial evaluating marizomib, pomalidomide and low‐dose dexamethasone in relapsed and refractory multiple myeloma (NPI‐0052‐107): final study results (2018) (50)
Growth inhibition and apoptosis of myeloma cells by the CDK inhibitor flavopiridol. (2002) (49)
Regulation of interleukin 6 in multiple myeloma and bone marrow stromal cells. (1995) (49)
Isolation and characterization of human multiple myeloma cell enriched populations. (2000) (49)
The 86-kD subunit of Ku autoantigen mediates homotypic and heterotypic adhesion of multiple myeloma cells. (1998) (48)
A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells. (2010) (48)
Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-β inhibitors (2005) (48)
Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism (2020) (47)
Novel therapies in the treatment of multiple myeloma. (2009) (45)
A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells (2016) (44)
A nano ultra-performance liquid chromatography-high resolution mass spectrometry approach for global metabolomic profiling and case study on drug-resistant multiple myeloma. (2014) (44)
A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib (2014) (43)
Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma (2007) (43)
The extracellular calcium Ca2+o-sensing receptor is expressed in myeloma cells and modulates cell proliferation. (2002) (42)
Synergistic anti‐myeloma activity of the proteasome inhibitor marizomib and the IMiD® immunomodulatory drug pomalidomide (2015) (42)
Perspectives for combination therapy to overcome drug-resistant multiple myeloma. (2005) (40)
Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients (2016) (39)
Targeting the UPS as therapy in multiple myeloma (2008) (39)
The treatment of relapsed and refractory multiple myeloma. (2007) (39)
Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. (2004) (37)
Role of interleukin 6 in the growth of myeloma-derived cell lines. (1992) (36)
Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of b1-integrin and phosphatidylinositol 3-kinase/AKT signaling beta. (2003) (36)
A novel agent SL-401 induces anti-myeloma activity by targeting plasmacytoid dendritic cells, osteoclastogenesis and cancer stem-like cells (2017) (34)
Interleukin-6 overcomes p21WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon-gamma in multiple myeloma cells. (1997) (34)
Patupilone (epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo. (2005) (33)
β-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells (2002) (33)
Targeting signalling pathways for the treatment of multiple myeloma (2005) (32)
p16INK4A promotes differentiation and inhibits apoptosis of JKB acute lymphoblastic leukemia cells. (1997) (32)
2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27 (2004) (32)
p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma. (2017) (32)
In vitro and In vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN 9708 Against Multiple Myeloma Cells (2011) (32)
A phase 1 study of oral CC5013, an immunomodulatory thalidomide (Thal) derivative, in patients with relapsed and refractory multiple myeloma (MM). (2001) (32)
Proteasomal Degradation of Topoisomerase I Is Preceded by c-Jun NH2-Terminal Kinase Activation, Fas Up-Regulation, and Poly(ADP-Ribose) Polymerase Cleavage in SN38-Mediated Cytotoxicity against Multiple Myeloma (2004) (32)
Interleukin‐6 is Required for Pristane‐Induced Plasma Cell Hyperplasia In Mice (1996) (31)
Apoptosis in multiple myeloma: Therapeutic implications (2001) (30)
Melflufen - a peptidase-potentiated alkylating agent in clinical trials (2017) (30)
Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma (2019) (29)
In vitro anti‐myeloma activity of the Aurora kinase inhibitor VE‐465 (2009) (29)
P38 MAPK Inhibition Enhances PS-341 (bortezomib)-Induced Cytotoxicity Against Multiple Myeloma Cells. (2004) (29)
Identification of upstream signals regulating interleukin-6 gene expression during in vitro treatment of human B cells with pokeweed mitogen. (1994) (28)
Melflufen - a peptidase-potentiated alkylating agent in clinical trials. (2017) (28)
Antitumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma (2014) (28)
Apoptotic Signaling in Multiple Myeloma: Therapeutic Implications (2003) (28)
The power of proteasome inhibition in multiple myeloma (2018) (28)
Functional interaction between retinoblastoma protein and stress-activated protein kinase in multiple myeloma cells. (1999) (27)
Regulation of c-jun gene expression in human T lymphocytes. (1993) (25)
Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation. (2020) (23)
Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status (2016) (22)
Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings (2011) (22)
Involvement of serum response element in okadaic acid-induced EGR-1 transcription in human T-cells. (1994) (20)
HDAC Inhibition by LBH 589 Affects Phenotype and Function of Human Myeloid Dendritic Cells (2013) (19)
Alkyl phospholipid perifosine induces myeloid hyperplasia in a murine myeloma model. (2007) (18)
in patients with multiple myeloma Elevated soluble MUC 1 levels and decreased anti-MUC 1 antibody levels (2000) (18)
Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells (2015) (18)
Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myeloma (2019) (17)
Targeting tryptophan catabolic kynurenine pathway enhances antitumor immunity and cytotoxicity in multiple myeloma (2019) (17)
A novel pre-B acute lymphoblastic leukemia cell line with chromosomal translocation between p16(INK4A)/p15(INK4B) tumor suppressor and immunoglobulin heavy chain genes: TGFbeta/IL-7 inhibitory signaling mechanism. (1996) (16)
Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation. (2021) (15)
Activation signals regulate heat shock transcription factor 1 in human B lymphocytes (1997) (15)
Novel targeted agents in the treatment of multiple myeloma. (2014) (14)
Role of CDK4 and p16INK4A in interleukin-6-mediated growth of multiple myeloma (1997) (14)
The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma (2020) (14)
MDM2 protein overexpression inhibits apoptosis of TF-1 granulocyte-macrophage colony-stimulating factor-dependent acute myeloblastic leukemia cells. (1998) (13)
Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma (2007) (13)
Erratum: Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma (Leukemia (2008) vol. 22 (1925-1932) 10.1038/leu.2008.174) (2008) (13)
Blockade of ubiquitin receptor Rpn13 in plasmacytoid dendritic cells triggers anti-myeloma immunity (2019) (12)
OP-106 Horizon — Melflufen Therapy for RRMM Patients Refractory to Daratumumab and/or Pomalidomide; Updated Results and First Report on PFS (2018) (12)
Combination of the mTOR inhibitor Rapamycin and Revlimid ( CC-5013 ) has synergistic activity in Multiple Myeloma (2004) (10)
A 3D‐Bioprinted Multiple Myeloma Model (2021) (10)
Phase 1, Multicenter, Open-Label, Combination Study (NPI-0052-107; NCT02103335) of Pomalidomide (POM), Marizomib (MRZ, NPI-0052), and Low-Dose Dexamethasone (LD-DEX) in Patients with Relapsed and Refractory Multiple Myeloma (2015) (10)
Dasatinib (BMS-354825): A Multi-Targeted Kinase Inhibitor with Activity Against Multiple Myeloma. (2005) (10)
The mTOR Inhibitor RAD001 (everolimus) Is Active Against Multiple Myeloma Cells In Vitro and in Vivo. (2004) (10)
Novel biologically based therapies for multiple myeloma (2002) (10)
Efficacy and safety of substituting teneligliptin with hydroxychloroquine in inadequately controlled type 2 diabetes subjects with combination therapy of teneligliptin, metformin and glimepiride with or without other antidiabetic therapy: The TENE-HYQ SHIFT Study (2018) (9)
Bortezomib in the management of multiple myeloma (2009) (9)
IPI-504: A Novel hsp90 Inhibitor with In Vitro and In Vivo Anti-Tumor Activity. (2004) (9)
Insulin-like Growth Factor-1 Induces Adhesion and Migration in Human Multiple Myeloma Cells via Activation of 1-Integrin and Phosphatidylinositol 3-Kinase / AKT Signaling 1 (2003) (9)
Elevated soluble MUC 1 levels and decreased anti-MUC 1 antibody levels in patients with multiple myeloma (2000) (9)
LAQ824 is a novel histone deacetylase inhibitor with significant activity against multiple myeloma: Results of a pre-clinical evaluation in vitro and in vivo. (2002) (8)
Resistance to Proteasome Inhibitors in Multiple Myeloma (2014) (8)
Results from Ongoing Phase 1/2 Trial of SL-401 in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (2016) (8)
Activation of pp90rsk and early growth response-1 gene expression by pokeweed mitogen in human B cells. (1995) (8)
Lenalidomide and Bortezomib Inhibit Osteoclast Differentiation and Activation in Multiple Myeloma: Clinical Implications. (2006) (8)
Deubiquitylating Enzyme USP-7, a Novel Therapeutic Target in Multiple Myeloma. (2009) (8)
Combination of a Novel Proteasome Inhibitor NPI-0052 and Lenalidomide Trigger in Vivo Synergistic Cytotoxicity in Multiple Myeloma (2008) (7)
Kaposi's sarcoma-associated herpesvirus gene sequences are detectable at low copy number in primary amyloidosis (2000) (7)
Anti-Tumor Activity of KOS-953, a Cremophor-Based Formulation of the hsp90 Inhibitor 17-AAG. (2004) (7)
Nifuroxazide Inhibits STAT3 Function and Shows Potent Anti-Tumor Activity Against Multiple Myeloma. (2006) (7)
CD 40 activation mediates p 53-dependent cell cycle regulation in human multiple myeloma cell lines (2000) (7)
beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells. (2002) (6)
Anti-Myeloma Activity of a Novel Free Radical Inducer Rrx-001 (2014) (6)
TGF-β Receptor I Kinase Inhibitor Downregulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment. (2004) (6)
Deubiquitylating Enzyme Rpn11/POH1/PSMD14 As Therapeutic Target in Multiple Myeloma (2016) (6)
Targeting Bcl-2 as Therapy for Multiple Myeloma. (2005) (6)
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma (2008) (6)
Multiple Myeloma - a New Era of Treatment Strategies (2012) (5)
Proteomic analysis identifies mechanism(s) of overcoming bortezomib resistance via targeting ubiquitin receptor Rpn13 (2020) (5)
Identification of novel anti-tumor therapeutic target via proteomic characterization of ubiquitin receptor ADRM1/Rpn13 (2021) (5)
Identification and validation of ecto-5' nucleotidase as an immunotherapeutic target in multiple myeloma (2022) (5)
A Novel Orally Available Proteasome Inhibitor NPI-0052 Induces Killing in Multiple Myeloma (MM) Cells Resistant to Conventional and Bortezomib Therapies. (2004) (5)
Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (2019) (5)
Targeting NAD+ Salvage Pathway Induces Autophagy in Multiple Myeloma Cells (2011) (5)
A proto-oncogene BCL 6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells (2010) (5)
CS1, a New Surface Target on Multiple Myeloma (MM) Cells, Protects Myeloma Cells from Apoptosis Via Regulation of ERK1/2, AKT and STAT3 Signaling Cascades. (2007) (5)
AZD6244 (ARRY-142886), a Potent and Selective MEK1/2 Inhibitor Blocks the ERK1/2 Signaling Pathway, Inhibits Osteoclast Differentiation and Activation in Multiple Myeloma: Clinical Implications. (2006) (4)
Pharmacodynamic and Efficacy Studies of a Novel Proteasome Inhibitor NPI-0052 in Human Plasmacytoma Xenograft Mouse Model (2008) (4)
The Proteasome Inhibitor NPI-0052 in Combination with Bortezomib Induces Antitumor Activity in Waldenstrom Macroglobulinemia. (2006) (4)
Promotes Differentiation and Inhibits Apoptosis of JKB Acute Lymphoblastic Leukemia Cells (1997) (4)
Effect of combination of proteasome inhibitor marizomib and immunomodulatory agent pomalidomide on synergistic cytotoxicity in multiple myeloma. (2014) (4)
Anti-Myeloma Activity of a Novel Glutaminase Inhibitor CB-839 (2014) (4)
Phase 1, multicenter, open-label, dose-escalation, combination study (NCT02103335) of pomalidomide (POM), marizomib (MRZ, NPI-0052), and dexamethasone (DEX) in patients with relapsed and refractory multiple myeloma (MM); study NPI-0052-107 preliminary results (2015) (4)
The PKC- Inhibitor Enzastaurin Inhibits MM Cell Growth, Survival and Migration in the Bone Marrow Microenvironment. (2005) (4)
2-methoxyestradiol (2ME2) acts directly on tumor cells and in the bone marrow microenvironment to overcome drug resistance in multiple myeloma (MM) cells. (2001) (4)
Distinct Dynamic Profiles for NPI-0052-And Bortezomib-Induced Apoptosis in Multiple Myeloma. (2006) (4)
FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma (2006) (3)
In vitro and in vivo activity of the VEGF receptor inhibitor PAZOPANIB (GW786034) in Multiple Myeloma: Therapeutic implications. (2006) (3)
Dysregulated CD4 + CD25 + T- Regulatory Cells and TLRs in Myeloma. (2004) (3)
Cancer Therapy : Preclinical In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN 9708 against Multiple Myeloma Cells (2011) (3)
Proteasome Inhibitors as Therapy in Multiple Myeloma (2008) (3)
Receptor activator of nuclear factor-kappa B (RANK) ligand expression: In human multiple myeloma cells. (2001) (3)
Combination of a Novel HDAC 6 Inhibitor ACY-241 with Anti-PD-L1 Antibody Enhances Anti-Tumor Immunity and Cytotoxicity in Multiple Myeloma (2016) (3)
Preclinical evaluation of a novel and orally active proteasome inhibitor as a therapy in relapsed/refractory multiple myeloma (2005) (3)
SL-401, A Novel Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Inhibits Plasmacytoid Dendritic Cell (pDC)-induced Myeloma Cell Growth and Overcomes Drug Resistance (2013) (3)
PR-924, a Selective Inhibitor of the Immunoproteasome Subunit LMP-7 Blocks Multiple Myeloma Cell Growth Both in Vitro and In Vivo. (2009) (3)
The Antidiabetic Biguanide Metformin Induces Growth Arrest in Multiple Myeloma Cells in Vitro, overcoming the Effect of Stromal Cells (2008) (3)
Proteasome inhibition, the pursuit of new cancer therapeutics, and the adaptor molecule p130Cas (2011) (3)
Potential Therapeutic Role of the Selective Adhesion Molecule (SAM) Inhibitor Natalizumab in Multiple Myeloma. (2009) (3)
antitumor activity in multiple myeloma Small-molecule inhibition of proteasome and aggresome function induces synergistic (2005) (3)
Vascular Endothelial Growth Factor (VEGF) -induced migration of Multiple Myeloma cells is associated with ββββ 1-integrin- and PI3-kinase- dependent PKC αααα activation (2001) (2)
Targeting Proteasome Ubiquitin Receptor RPN13/ADRM1 in Multiple Myeloma (2014) (2)
Emerging treatments of multiple myeloma; beyond IMIDs and bortezomib (2009) (2)
Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma (2000) (2)
Synergistic Anti-Myeloma Activity of a Proteasome Inhibitor Marizomib and IMiD® Immunomodulatory Drug Pomalidomide (2014) (2)
AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor Induces Antimyeloma Activity Via Potent Aurora Kinase and STAT3 Inhibition. (2009) (2)
SL-401, a Novel IL-3Rα/CD123-Directed Agent Targets Stem-like Cells in Multiple Myeloma (2016) (2)
Combination of Anti-PD-L1 Antibody with IMiD® Immunomodulatory Drugs, HDAC Inhibitor ACY-1215, Bortezomib, or Toll-like Receptor 9 Agonist Enhances Anti-Tumor Immunity and Cytotoxicity in Multiple Myeloma (2015) (2)
JS-K, a GST-Activated Nitric Oxide Generator, Induces DNA-Double Strand Breaks and Inhibits Growth and Survival of Multiple Myeloma Cells In Vitro and In Vivo. (2006) (2)
Gabarap Loss Mediates Immune Escape in High Risk Multiple Myeloma (2021) (2)
Proteasome Stress Causes Apoptotic Sensitivity of Multiple Myeloma Cells to Proteasome Inhibition (2008) (2)
Heat shock protein-27 confers drug-resistance in multiple myeloma cells. (2002) (2)
Function and expression of checkpoint inhibitors and immune agonists on immune cells in monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM) and MM and tumor-specific T lymphocytes. (2017) (2)
Lenalidomide and bortezomib induce osteoclast cytotoxicity and decrease BAFF secretion in osteoclasts in human multiple myeloma: Clinical implications. (2006) (2)
Targeting MEK1/2 Signaling Cascade by AS703026, a Novel Selective MEK1/2 Inhibitor, Induces Pleiotropic Anti-Myeloma Activity in Vitro and In Vivo. (2009) (2)
A MIR17HG-derived Long Noncoding RNA Provides an Essential Chromatin Scaffold for Protein Interaction and Myeloma Growth. (2022) (2)
Mitochondria and caspase-independent cell-death triggered by GCS-100, a novel carbohydrate-based therapeutic in multiple myeloma (MM) cells. (2004) (2)
Interaction of Plasmacytoid Dendritic Cells and Myeloma Cells Trigger Tumor Promoting Transcriptional Changes in Multiple Myeloma Cells (2019) (2)
Bortezomib induces canonical nuclear factor- (cid:1) B activation in multiple myeloma cells (2009) (2)
Cells : Clinical Implications Antibody , Induces Cytotoxicity in Human Multiple Myeloma Mechanisms by which SGN-40 , a Humanized Anti-CD 40 (2004) (2)
Investigational Agent MLN9708 Target Tumor Suppressor MicroRNA-33b in Multiple Myeloma Cells (2011) (2)
PKC412 Is a Multi-Targeting Kinase Inhibitor with Activity Against Multiple Myeloma In Vitro and In Vivo. (2005) (2)
Targeting mitochondria to overcome conventional and Bortezomib-resistance in multiple myeloma cells. (2003) (2)
Targeting 19S-Proteasome Deubiquitinase Rpn11/POH1/PSMD14 in Multiple Myeloma (2015) (2)
Plasmacytoid Dendritic Cells Induce Growth and Survival of Multiple Myeloma Cells: Therapeutic Application. (2007) (2)
AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor with Potent Activity Against Aurora Kinase and STAT3 In Combination with Lenalidomide Results In Synergistic Anti-Myeloma Activity (2010) (2)
Anti-Myeloma Activity of the Small-Molecule Aurora Kinase Inhibitor VE465. (2006) (2)
Critical role for Hck-mediated phosphorylation of Gab1 and Gab2 docking proteins in interleukin-6-induced proliferation and survival of multiple myeloma cells. (2003) (2)
Antimyeloma Efficacy of Plitidepsin (Aplidin®): From Bench to the Bedside. (2007) (2)
Pathophysiologic role of VEGF in hematologic malignancies (2007) (2)
Lenalidomide and Bortezomib: Targeting Osteoclastogenesis, Osteoclast Survival Factors, and Bone Remodeling Markers in Multiple Myeloma. (2007) (2)
Targeting ubiquitin-specific protease-7 in plasmacytoid dendritic cells triggers anti-myeloma immunity (2021) (2)
Effects of the indazolylpyrimidine GW786034 on angiogenesis and MM cell growth: Therapeutic implications. (2004) (2)
HDAC Inhibition by LBH589 Affects Phenotype and Function of Human Dendritic Cells. (2009) (2)
Mechanisms, biologic sequelae and clinical benefits of bortezomib-induced immunogenic cell death in multiple myeloma (2019) (2)
Novel hydroxamic acid-derived HDAC inhibitor LBH589 potently activates intrinsic and extrinsic apoptotic pathways, and induces tubulin hyperacetylation in multiple myeloma. (2005) (2)
Pharmacodynamic profiling defines the significant biological activities of the novel proteasome inhibitor NPI-0052: Comparison with Velcade® (Bortezomib) (2006) (1)
Novel Combination Therapies for the Treatment of Relapsed/Refractory Multiple Myeloma: Current Phase I/II Combinations (2009) (1)
The Small-Molecule VEGF-Receptor Inhibitor Pazopanib (GW786034B) Targets Both Tumor and Endothelial Cells in Multiple Myeloma. (2006) (1)
Advances in Brief Functional Interaction between Retinoblastoma Protein and Stress-activated Protein Kinase in Multiple Myeloma Cells 1 (1999) (1)
Proteomic Analysis Identifies Mechanism(s) of Overcoming Bortezomib-Resistance Via Targeting Ubiquitin Receptor Rpn13 (2019) (1)
A Novel SIRT1 Activator SIRT1720 Triggers In Vitro and In Vivo Cytotoxicity In Multiple Myeloma Via ATM-Dependent Mechanism (2010) (1)
Compositions and methods for the treatment of neoplastic diseases (2005) (1)
Abstract C94: Deubiquitylases as novel anticancer targets: Discovery and development of novel USP7 inhibitors (2009) (1)
Gene expression analysis of tumor cells sensitive and resistant to PS-341 (Bortezomib) treatment: Clinical implications. (2003) (1)
C-Myc- Dependent Stabilization of Hif-1alpha in MM: Therapeutic Implications (2008) (1)
A Novel Agent SL-401 Triggers Anti-Myeloma Activity By Targeting Plasmacytoid Dendritic Cells: Implications for a Novel Immune-Associated Mechanism (2015) (1)
NVP-AEW541: A Selective Small Molecule IGF-1R Tyrosine Kinase Inhibitor Is Active Against Multiple Myeloma and Other Hematologic Neoplasias and Solid Tumors. (2004) (1)
Bcl6 as a Novel Therapeutic Target in Multiple Myeloma (MM). (2009) (1)
beta-Lapachone is safe and effective in Biege-Nude-Xid mouse xenograft model of human plasmacytoma. (2001) (1)
Interactions of the Mdm2/p53 and Proteasome Pathways: Implications for Combination Strategies to Enhance the Anti-Myeloma Activity of Bortezomib (2008) (1)
Critical role for Hck-mediated phosphorylation of Gab1 and Gab2 docking proteins in IL-6- induced proliferation and survival of MM cells (2004) (1)
Expression and Modulation of Carbohydrate-Binding Protein Galectin-3 in Multiple Myeloma Cells by Combined Treatment with GCS-100 and Dexamethasone. (2005) (1)
synergistic in myeloma cells hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are -tubulin α Aggresome induction by proteasome inhibitor bortezomib and (2013) (1)
Blockade of Ubiquitin Receptor PSMD4/Rpn10 Triggers Cytotoxicity and Overcomes Bortezomib-Resistance in Multiple Myeloma (2018) (1)
In vitro and in vivo proteasome activity profiles of bortezomib and a novel proteasome inhibitor NPI-0052 (2005) (1)
Blockade of Deubiquitylating Enzyme USP7 in Plasmacytoid Dendritic Cells Stimulates Anti-Myeloma Immunity (2020) (1)
1 JSK , a GST-activated nitric oxide generator , induces DNA double strand breaks , activates DNA damage response pathways , and induces apoptosis in vitro and in vivo in human multiple myeloma cells (2007) (1)
A High Throughput Quantitative Seroproteomics Analysis of Multiple Myeloma Patients on Tagraxofusp Therapy Identifies Novel Cytokine-Assisted Mechanism of Action (2020) (1)
Atiprimod (N-N-diethl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) Inhibits Myeloma in Vivo. (2004) (1)
MLN 120 B , a Novel I K BKinase B Inhibitor , Blocks Multiple Myeloma Cell Growth In vitro and In vivo (2006) (1)
inhibition myeloma cells via mTORC 1 and extracellular signal-regulated kinase salvage pathway induces autophagy in multiple + Targeting NAD (2012) (1)
Pancreas Cancer Molecular Targets for Therapy (2011) (1)
Targeting Cyclin D1 in the Treatment of Multiple Myeloma: Preclinical Validation of a Novel Specific Small Molecule Cyclin D1 Inhibitor, P276-00. (2006) (1)
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy (2000) (1)
Abstract 2530: Antimyeloma activity of a small molecule multi-targeted kinase inhibitor, AT9283, via potent aurora kinase and STAT3 inhibition (2010) (1)
Biological correlates to support a clinical role for tagraxofusp, a novel targeted therapy directed to CD123, in combination with pomalidomide and dexamethasone, to target plasmacytoid dendritic cells in poor-risk patients with multiple myeloma. (2020) (1)
A Novel Alkylating Agent Melphalan Flufenamide Ethyl Ester Induces an Irreversible DNA Damage in Multiple Myeloma Cells (2014) (1)
Endothelial Cells Induce Multiple Myeloma Cell Proliferation Protect Against Conventional and Novel Therapies. (2004) (1)
Cytokines and Signal Transduction in Multiple Myeloma (2013) (1)
Effect of a novel agent, SL-401, targeting interleukin-3 receptor (IL-3R) on plasmacytoid dendritic cell (pDC)-induced myeloma cell growth and osteolytic bone disease. (2014) (1)
A 3D‐Bioprinted Multiple Myeloma Model (Adv. Healthcare Mater. 7/2022) (2022) (1)
Assessing proteasome workload to predict response and overcome resistance to proteasome inhibitors in multiple myeloma (2007) (1)
Targeting Cell-Death Pathways in Multiple Myeloma: Therapeutic Implications (2005) (1)
Targeting Tryptophan Catabolic Kynurenine Pathway Enhances Anti-Tumor Immunity and Cytotoxicity in Multiple Myeloma (2018) (1)
Requirement of Caspase-8 Versus Caspase-9 during Apoptosis in Multiple Myeloma Cells Induced by Bortezomib- or a Novel Proteasome Inhibitor NPI-0052. (2005) (1)
Dysfunctional T Regulatory Cells in Myeloma: Molecular Mechanisms of Dysregulation. (2005) (1)
Intracellular NAD + Depletion Enhances Bortezomib-Induced Myeloma Cytotoxicity (2012) (1)
The In Vivo Activity of Neutralizing B Cell-Activating Factor (BAFF) Antibody in the Treatment of Multiple Myeloma (MM). (2006) (1)
Anti-Tumor Activity of a Novel Immunosuppressant FTY720 in Multiple Myeloma. (2004) (1)
PtdIns 3-kinase (2011) (1)
R-Etodolac and a Novel Indole-Pyran Structural Analog, SDX-308, Induce Cytotoxicity and Overcome Drug Resistance in Multiple Myeloma. (2005) (1)
Reversine: A Chemical Probe Providing Insight into Myeloma Biology and Potential Therapeutic Applications. (2006) (1)
JS-K, a GST-Activated Nitric Oxide Generator, Induces Apoptosis and Overcomes In Vitro Drug Resistance in Multiple Myeloma Cells. (2005) (1)
Direct Assessment of Proteasomal Degradation as a Potential Predictor of Responsiveness to Bortezomib in Multiple Myeloma (2006) (0)
Antitumor activity of the maytansinoid immunoconjugate B-B4 (B-B4-DM1) against CD138+multiple myeloma cells. (2003) (0)
Proteasome inhibition regulates survival and homing in Waldenstrom Macroglobulinemia (WM) (2008) (0)
Compromised Nuclear Sirtuins Activity Sensitizes BRCA-Proficient multiple Myeloma Cells to DNA Damage Agents (2012) (0)
Effect of Thalidomide and Revlimid on the Gene Expression That Reveals Molecular Circuitries Involved in T Cell Co-Activation. (2004) (0)
OAB-009: Genome-wide CRISPR interference screen identifies RNA Regulator of Lipogenesis (RROL) as a leading LncRNA dependency in Multiple Myeloma (2021) (0)
Targeting Src-family kinase activation and downstream molecular events to overcome MM cell growth, survival, and drug-resistance. (2005) (0)
Preclinical Validation of Ubiquitin Receptor PSMD4 As Therapeutic Target in Multiple Myeloma (2019) (0)
Enhanced cytotoxicity of monoclonal antibody SGN-40 and immunomodulatory drug IMiD3 against human multiple myeloma (2004) (0)
Chapter 2 Resistance to Proteasome Inhibitors in Multiple Myeloma (2017) (0)
Role of ubiquitin-conjugating enzyme CDC34 in multiple myeloma. (2003) (0)
The Novel, Orally Available Multi-Kinase Inhibitor BAY 73-4506 in Multiple Myeloma (2008) (0)
against apoptosis VEGF induces MCL-1 upregulation and protects multiple myeloma cells (2013) (0)
Myeloma Resistance and is Well Tolerated in Patients with Relapse Multiple Immunomodulatory Derivative of Thalidomide CC-5013 Overcomes Drug (2013) (0)
Abstract 2074: ORIC-533, a small molecule CD73 inhibitor with best-in-class properties, reversesimmunosuppression and has potential as an immunomodulatory therapy in patients with multiple myeloma (2022) (0)
Targeting Ubiquitin Receptor Rpn13/ADRM1 in Plasmacytoid Dendritic Cells Enhances Anti-Myeloma Immunity (2019) (0)
Detection of Kaposi's Sarcoma Herpesvirus Gene Sequences Multiple Myeloma Are Phenotypically and Functionally Normal Despite the Bone Marrow and Peripheral Blood Dendritic Cells From Patients With (2008) (0)
malignant B cells Molecular sequelae of histone deacetylase inhibition in human (2013) (0)
Increased Sensitivity to DNA Damage Multiple Myeloma Cells Is Associated with Ku86 Variant Expression and Function in (2013) (0)
Targeting Deubiquitylating Enzyme USP1 in Multiple Myeloma (2015) (0)
Molecular Characterization of PS-341 (bortezomib) Resistance: Implications for Overcoming Resistance Using Lysophosphatidic Acid Acyltransferase (LPAAT)-β Inhibitors. (2004) (0)
Effect of a novel agent, SL-401, targeting interleukin-3 (IL-3)-receptor on plasmacytoid dendritic cell (pDC)-induced myeloma cell growth and drug resistance. (2013) (0)
Scientific section designations: Lymphoid Neoplasia Title: p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma Short title: TP53RK is a novel therapeutic target in myeloma (2016) (0)
JNK activation and Fas up-regulation precede proteasomal degradation of topoisomerase I in SN38-mediated cytotoxicity against multiple myeloma. (2004) (0)
OAB-033: Loss-of-function of GABARAP drives tumor resistance to bortezomib-induced immunogenic cell death in multiple myeloma (2021) (0)
Evaluation of the Specificity and Cytotoxicity of Three Proteasome Inhibitors. (2005) (0)
The novel proteasome inhibitor BzLLL-COCHO is a specific inhibitor of proteasome activity (2005) (0)
Targeting IKK Inhibits Multiple Myeloma (MM) Cell Growth in the Bone Marrow Microenvironment. (2004) (0)
Clinical implications for optimizing the approach to topoisomerase 1 as a therapeutic target in multiple myeloma (MM). (2003) (0)
Biological pathways and in vivo anti-tumor activity induced by atiprimod in multiple myeloma (MM). (2006) (0)
P-108: An antisense platform for the pre-clinical development of novel LncRNA inhibitors in multiple myeloma (2022) (0)
NPI-2358, a Novel Vascular Disrupting Agent Blocks Growth and Angiogenesis in Multiple Myeloma Cells. (2009) (0)
PI3-kinase- dependent PKCα activation (2001) (0)
microenvironment migration of multiple myeloma cells in the bone marrow GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and (2013) (0)
IMW Section B (2009) (0)
Up-Regulation of c-Jun contributes to the Induction of Apoptosis by Adaphostin in Human Multiple Myeloma Cells. (2005) (0)
Long Noncoding RNA RROL Provides Chromatin Scaffold for MYC-WDR82 Interaction to Impact Lipid Metabolism and Tumor Cell Growth in Multiple Myeloma (2021) (0)
synergistic activity in multiple myeloma Combination of the mTOR inhibitor rapamycin and CC-5013 has (2013) (0)
multiple myeloma cell lines CD40 activation mediates p53-dependent cell cycle regulation in human (2008) (0)
Mcl-1 Fragment Mcl-1(128–350) Induces Inhibition of Multiple Myeloma Cell Proliferation and Apoptosis Via Both Upregulation of C-Jun as Well as Modulation of Its Transcriptional Activity (2008) (0)
P-085: Resistance to immunogenic cell death as a novel mechanism of immune escape in high-risk multiple myeloma (2022) (0)
synergistic cytotoxicity in multiple myeloma vivo in Combination of proteasome inhibitors bortezomib and NPI-0052 trigger (2012) (0)
RNA Regulator of Lipogenesis (RROL) Is a Novel Lncrna Mediating Protein-Protein Interaction at Gene Regulatory Loci Driving Lipogenic Programs in Multiple Myeloma (2020) (0)
Blockade of Ubiquitin Receptor Rpn13 in Plasmacytoid Dendritic Cells Enhances Anti-Myeloma Immunity (2019) (0)
In vitro and in vivo antitumor activity of the maytansinoid immunoconjugate BB-10901 (huN901-DM1) on CD56+multiple myeloma cells. (2003) (0)
In Vitro Activity of a Novel Small Molecule Cyclin Dependent Kinase Inhibitor, CYC202 (seliciclib or R-Roscovitine), in Multiple Myeloma (MM). (2004) (0)
Targeting Proteinkinase C Alters ER-Stress and b-Catenin Signaling in Multiple Myeloma: Therapeutic Implications. (2007) (0)
Role Of Sirtuin-6 In Maintenance Of Genomic Instability In Multiple Myeloma Cells (2013) (0)
B026 CS1 Promotes Multiple Myeloma Cell Adhesion, Clonogenic Growth, and Tumorigenicity via c-Maf Mediation (2009) (0)
The Novel, Orally Available Multi-Kinase Inhibitor BAY 73-4506 Targets Myeloma Cells and Their Bone Marrow Microenvironment. (2007) (0)
BIRB796 Inhibits p38 MAPK/Hsp27 Pathway and Enhances Cytotoxicity Triggered by Bortezomib, Hsp90 Inhibitor, and Dexamethasone in Multiple Myeloma. (2006) (0)
Upregulation of c-Jun Induces Cell Death Via Caspase-Triggered c-Abl Cleavage in Human Multiple Myeloma. (2006) (0)
Lymphoblastic Leukemia Cells Promotes Differentiation and Inhibits Apoptosis of JKB AcuteINK 4 Ap (1997) (0)
Ubiquitin Receptor PSMD4/Rpn10 Is a Novel Therapeutic Target in Myeloma (2021) (0)
Targeting the Ubiquitin-proteasome System in Multiple Myeloma: Examining the Roots of Success (2015) (0)
A novel non-peptide and orally active proteasome inhibitor overcomes bortezomib-resistance in multiple myeloma (MM) cells (2005) (0)
Primary Cancer Site (2011) (0)
Cytokines in Multiple Myeloma (2007) (0)
Bcl-2, Mcl-1 and p53 Expression Confer Sensitivity to Bcl-2 Inhibitor ABT-737 in Multiple Myeloma. (2006) (0)
Loss-of-Function of Gabarap Impairs Bortezomib-Induced Anti-Tumor Immunity in Multiple Myeloma: Clinical Application (2019) (0)
Multiple Myeloma Cells MDM2 Protein Overexpression Promotes Proliferation and Survival of (2008) (0)
Upregulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma and other malignancies (2007) (0)
Targeting therapy for resistant multiple myeloma with a novel inhibitor of NF-KB, NPI-1387. (2005) (0)
Oral Proteasome Inhibitor Marizomib and IMiD® Imunomodulatory Drug Pomalidomide Trigger Synergistic Anti-Myeloma Activity and Enhanced Proteasome Inhibition in Vitro and In Vivo (2015) (0)
Proteasome inhibitors: beyond NFKB inhibition alone and the emerging role of combination therapy in the treatment of multiple myeloma (2009) (0)
Correction: Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myeloma (2021) (0)
The Hypoxia-Selective Epigenetic Agent, Rrx-001, Triggers Apoptosis and Overcomes Drug-Resistance in Multiple Myeloma Cells (2015) (0)
A Novel Acanthoic Acid Analog NPI-1342 Blocks IκB Kinase-α and Trigger In Vitro and In Vivo cytotoxicity in Multiple Myeloma Cells (2011) (0)
Identification of Alpha-Enolase (ENO1) As a Novel Immunometabolic Target in Multiple Myeloma (2018) (0)
Novel Etodolac Analog SDX-308 (CEP-18082) Induces Cytotoxicity in Multiple Myeloma Cells Associated with Inhibition of Wnt/β-Catenin Pathway. (2006) (0)
The role of membrane raft in modulating CD40 signaling, ERK activation and cytokine production in human multiple myeloma cells. (2003) (0)
Akt Inhibitor Perifosine-Induced Cytotoxicity Is Associated with Significant Downregulation of Survivin in Human Multiple Myeloma (MM) Cells. (2006) (0)
Biology and Prognostic Implications of Bone Marrow Plasmacytoid Dendritic Cells in Multiple Myeloma Pathogenesis By Single-Cell RNA Sequencing (2022) (0)
Identification of Novel Antigens with Induced Immune Response in MGUS. (2006) (0)
Inhibition of Ubiquitin Receptor PSMD4/Rpn10 as Therapeutic Strategy to Overcomes Bortezomib-Resistance in Multiple Myeloma cells (2019) (0)
Caveolin-1 Is Required for VEGF- Triggered Multiple Myeloma Cell Migration and Is Targeted by Bortezomib (Velcade®). (2004) (0)
The Polycomb Group Transcriptional Repressor Bmi-1 Is Constitutively Expressed in Multiple Myeloma (MM) Cells and Modulates Proliferation through a Mechanism Independent of the Ink4a/ARF Locus. (2004) (0)
Population Candidate Gene Association Study (2011) (0)
Cancer Therapy : Preclinical Preclinical Activity of theOral Proteasome InhibitorMLN 9708 in Myeloma Bone Disease (2014) (0)
Delineation of Canonical and Non-Canonical NF-κB Pathways in Multiple Myeloma: Therapeutic Implications. (2007) (0)
HUWE1 Inhibition As a Therapeutic Strategy to Target MYC in MM (2017) (0)
The Biological Sequelae of Stromal Cell-derived Factor-1 (cid:1) in Multiple Myeloma 1 (2002) (0)
Alkylphosphocholine Perifosine Inhibits Myeloma Cell Growth While Inducing Myeloid Hyperplasia in a Murine Myeloma Model. (2005) (0)
MLN120B, a Novel IKBKinase B Inhibitor, Blocks Multiple Myeloma Cell Growth In vitro and In vivo (2006) (0)
(LY317615.HCl) novel, orally available small-molecule inhibitor enzastaurin Targeting PKC in multiple myeloma: in vitro and in vivo effects of the (2013) (0)
Identification Of Novel Alternative Splice Variants Of Sirtuins In Multiple Myeloma: Therapeutic Implications (2013) (0)
Sulforaphane and PEITC Augment Activity of Conventional and Novel Anti-Myeloma Drugs (2008) (0)
Lymphoblastic Leukemia Cells Promotes Differentiation and Inhibits Apoptosis of JKB Acute INK4A p16 (2008) (0)
The JAK inhibitor INCB20 induces antiproliferative and apoptotic effects in human myeloma cells in vitro and in vivo (2005) (0)
P-097: Preclinical validation of Ecto-5’ Nucleotidase (NT5E/CD73) as a novel immunotherapeutic target in Multiple Myeloma (2021) (0)
Bioprocessing of MIR17HG Results in Long and Short Noncoding RNAs with Targetable Tumor-Promoting Activity in Multiple Myeloma (2022) (0)
Inhibition of Kynurenine-3-Monooxygenase in Tryptophan Catabolic Kynurenine Pathway Enhances Anti-Myeloma Immunity (2019) (0)
CD73 Inhibition Reverses Immunosuppression and Has Potential As an Immunomodulatory Therapy in Patients with Multiple Myeloma (2022) (0)
Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism (2020) (0)
inhibiting STAT3 Nifuroxazide inhibits survival of multiple myeloma cells by directly (2013) (0)
The novel, orally available small- molecule PKC inhibitor enzastaurin (LY317615.HCl) in multiple myeloma: in vitro and in vivo effects and therapeutic implications (2007) (0)
Abstract A21: Inhibition of USP7 for the treatment of multiple myeloma and other malignancies. (2015) (0)
26S Proteasome Non-Atpase Subunit 1, PSMD1/Rpn2, Is a Potential Therapeutic Target in Multiple Myeloma (2022) (0)
Niches Within the Multiple Myeloma Bone Marrow Microenvironment (2007) (0)
therapeutic applications B blockade in multiple myeloma: κ - Biologic sequelae of nuclear factor (2013) (0)
An Investigational Novel Orally Bioavailable Proteasome Inhibitor MLN9708/MLN2238 Triggers Cytotoxicity In Multiple Myeloma Cells Via p21- and Caspase-8-Dependent Signaling Pathway (2010) (0)
Defining a Murine Model To Study Bone Disease in Multiple Myeloma (MM). (2006) (0)
Anti-Tumor Activities of XBP1 Antigen-Specific Cytotoxic T Lymphocytes Are Enhanced By HDAC6 Inhibitor ACY241 (2016) (0)
A Novel Inosine Monophosphate Dehydrogenase Inhibitor VX-944 Overcomes Conventional Drug-Resistance in Multiple Mueloma Cells in the Bone Marrow Microenvironment. (2004) (0)
VEGF Upregulates Mcl-1 Expression and Protects Multiple Myeloma Cells Against Starvation Induced-Apoptosis. (2004) (0)
Novel Cytokine-Mediated Mechanism of Action Identified By Quantitative Seroproteomics in Multiple Myeloma Patients Treated with Tagraxofusp, a Novel CD123-Directed Targeted Therapy (2021) (0)
Deubiquitylating Enzyme USP1 As Therapeutic Target in Multiple Myeloma (2016) (0)
Phase 1/2 dose-escalation study of marizomib (MRZ, NPI-0052) plus low dose dexamethasone (DEX) in patients with relapsed and refractory multiple myeloma; study NPI-0052-101 (NCT00461045) (2015) (0)
Plasmacytoid Dendritic Cells Trigger Contact-Dependent Tumor Promoting Genetic Alterations in Multiple Myeloma Cells (2018) (0)
Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma. (2023) (0)
Antitumor Activities Of An Oral Selective HSP90α/β Inhibitor, TAS-116, In Combination With Bortezomib In Multiple Myeloma (2013) (0)
Proteomic Characterization of Ubiquitin Receptor ADRM1/Rpn13 (2020) (0)
Bcl-B and Nur77/TR3: a deadly combination (2007) (0)
Identification of novel anti-tumor therapeutic target via proteomic characterization of ubiquitin receptor ADRM1/Rpn13 (2021) (0)
Histone Deacetylase Inhibitors Demonstrate Significant Preclinical Activity as Single Agents, and in Combination with Bortezomib in Waldenstrom's Macroglobulinemia. (2009) (0)
Analysis of COVID-19-Associated Proteins Identifies TANK-Binding Kinase 1 As an Immunotherapeutic Target in Multiple Myeloma (2022) (0)
Cancer Therapy : Preclinical In Vitro and In Vivo Antitumor Activity of a Novel Alkylating Agent , Melphalan-Flufenamide , against Multiple Myeloma Cells (2013) (0)
in vivo synergistic cytotoxicity in multiple myeloma Combination of proteasome inhibitors bortezomib and NPI-0052 trigger (2008) (0)
by Dexamethasone Muc-1 Core Protein Is Expressed on Multiple Myeloma Cells and Is Induced (2013) (0)
Histone Deacetylase-6 (HDAC6) Modulates Akt and STAT3 Activity Via Heat Shock Protein (Hsp) 90 in Human Multiple Myeloma (MM) Cells. (2006) (0)
Monoclonal Antibody–Based Therapies in Human Multiple Myeloma (2009) (0)
Activation of B-Cell Maturation Antigen (BCMA) on Human Multiple Myeloma Cells by a Proliferation-Inducing Ligand (APRIL) Promotes Myeloma Cell Function in the Bone Marrow Microenvironment. (2007) (0)
B454 Mcl-1 Fragment Mcl-1128-350 Induces Inhibition of Multiple Myeloma Cell Proliferation and Apoptosis (2009) (0)
The Tyrophostin Adaphostin (NSC680410) Inhibits Multiple Myeloma Bone Marrow Angiogenesis In Vitro and In Vivo. (2007) (0)
proteasome inhibitor PS-341 resistance in multiple Targeting mitochondria to overcome conventional and (2004) (0)
Anti-Myeloma Activity of Enzymatically Activated Melphalan Prodrug J1 (2010) (0)
Targeting Autophagy to Overcome Resistance to Immunogenic Chemotherapy in High-Risk Multiple Myeloma (2022) (0)
Molecular Sequaele of Activin A-Dependent Osteoblast Inhibition in Myeloma. (2009) (0)
marrow milieu Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone (2013) (0)
Analysis of Sars-Cov-2-Associated Proteins Identify Tank-Binding Kinase-1 As an Immunotherapeutic Target in Multiple Myeloma (2020) (0)
beta-lapachone, a novel topoisomerase I inhibitor, has significant cytotoxicity against multiple myeloma (MM) cell lines and patient cells. (2001) (0)
B341 BAY 73-4506, A Novel Orally Available Multikinase Inhibitor in MM (2009) (0)
Increased TCF-4 Expression Correlates with Reduced Caspase-3 Induction and Confers Resistance to Bortezomib. (2004) (0)
PreclinicalActivityoftheOralProteasomeInhibitorMLN9708 in Myeloma Bone Disease (2014) (0)
P-086: Quantitative seroproteomics analysis of Multiple Myeloma patients treated with Tagraxofusp, a novel CD123-directed targeted therapy, identifies novel cytokine-mediated mechanism of action (2021) (0)
CYC202 (seliciclib or R-Roscovitine), a small molecule cyclin dependent kinase inhibitor, overcomes drug resistance via down-regulation of Mcl-1 in multiple myeloma (MM) (2005) (0)
A Novel Agent SL-401 Targeting Interleukin-3 (IL-3)-Receptor Blocks Plasmacytoid Dendritic Cell (pDC)-induced Myeloma Cell Growth and Overcomes Drug Resistance (2009) (0)
Modulation of Signaling Cascades by Inhibitors of Histone Deacetylase and Akt (2009) (0)
Identification and Validation of HLA-A24 XBP1us, XBP1sp, CD138, and CS1 Peptides to Generate Antigens Specific-Cytotoxic T Lymphocytes: Preclinical Basis for Vaccine Therapy in HLA-A24 Patients with Multiple Myeloma and Other Cancers (2016) (0)
Cancer Therapy: Preclinical In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells (2011) (0)
16(4A Expression in Multiple Myeloma and Plasma Cell Leukemia (1997) (0)
A Small Molecule-induced Targeted Degradation of Ubiquitin Receptor Rpn13 as a Novel Therapeutic Strategy in Multiple Myeloma (2019) (0)
Preclinical Validation of a Clinical Grade Novel Specific Small Molecule Cyclin D1 Inhibitor, P276-00 for the Treatment of Multiple Myeloma. (2007) (0)
Bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic apoptosis in multiple myeloma (MM) cells (2003) (0)
The Biologic Relevance of PIM Kinases in the Context of Multiple Myeloma and Their Potential As Therapeutic Targets in Combination Drug Therapy (2015) (0)
Inhibition of human plasmacytoma cell growth by a novel JAK kinase inhibitor. (2004) (0)
P-093: Ubiquitin receptor PSMD4/Rpn10 as therapeutic target in Multiple Myeloma (2021) (0)
Profiling proteasome activity in multiple myeloma and lymphoma (2004) (0)
Differential oxidative stress responses during 2-methoxyestradiol (2ME2) and dexamthasone (Dex)-induced apoptosis in multiple myeloma (MM) cells. (2002) (0)
Myeloma Bone Marrow Stromal Cells Detection of Kaposi's Sarcoma Herpesvirus DNA Sequences in Multiple (2013) (0)
Combination of Melphalan Flufenamide and Anti-PD-L1 or Anti-CD38 Antibodies Enhances Anti-Myeloma Immunity (2021) (0)
SL-401, a Novel Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Blocks Plasmacytoid Dendritic Cell (pDC)-Triggered Myeloma Cell Growth and Prevents Osteoclastogenesis (2014) (0)
Targeting Proteasome- Associated Ubiquitin Receptor PSMD4/Rpn10 in Multiple Myeloma (2017) (0)
The proteasome and proteasome inhibitors in multiple myeloma (2017) (0)
New Therapeutic Strategies in Multiple Myeloma (2012) (0)
Proteasome activity is cell-type dependent. (2003) (0)
p38MAPK Inhibitor LSN2322600 Modulates the Bone Marrow Microenvironment and Inhibits Osteoclastogenesis in Multiple Myeloma. (2006) (0)
A chimeric humanized anti-CD40 antibody renders human multiple myeloma (MM) cells refractory to the mitogenic and protective effects of IL-6 (2003) (0)
Role of BAFF in Adhesion and Growth of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment. (2005) (0)
The Tyrosine Kinase Inhibitor Adaphostin (NSC 680410), but Not Imatinib Mesylate, Inhibits Survival and Src Tyrosine Kinase Family- Triggered Signaling Pathways of MM Cells. (2004) (0)
apoptosis myeloma by induction of caspase-dependent and -independent Honokiol overcomes conventional drug resistance in human multiple (2010) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Dharminder Chauhan?

Dharminder Chauhan is affiliated with the following schools:

Dharminder Chauhan's Academic­Influence.com Rankings

Dharminder Chauhan's Degrees

Why Is Dharminder Chauhan Influential?

Dharminder Chauhan's Published Works

Published Works

What Schools Are Affiliated With Dharminder Chauhan?

Dharminder Chauhan's AcademicInfluence.com Rankings